Biodexa Pharmaceuticals PLC
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Biodexa Pharmaceuticals PLC
Back From The Dead Biodexa Makes Bid For VarianBio
Having just avoided going into administration, the firm formerly known as Midatech has pivoted its business model from a drug delivery company to a therapeutics player and has hit the acquisition trail.
Midatech Survival Plan Scuppered By Shareholders
The UK firm's shareholders have not approved plans to acquire Bioasis, a decision that puts Midatech in a tricky situation as its cash will run out by mid-March.
Midatech Bets on Bioasis Merger For Survival
With just enough cash to stay afloat until the first quarter, Midatech is linking up with US-based, Canada-listed Bioasis to create a new rare disease player, Biodexa.
New CEO of Renamed Spin-Out Fortovia Therapeutics Will Be ‘Solely US-Focused’
Newly installed Fortovia Therapeutics CEO Peter Melnyk tells Scrip his arrival and the company’s name change from Midatech Pharma US signals a strategic revamp for the privately held spin-out.
- Specialty Pharmaceuticals
- Controlled Release
- Site Specific
- Nanotechnology, Chips, etc.
- Other Names / Subsidiaries
- DARA BioSciences, Inc.
- MidaSol Therapeutics LP
- Midatech Group Ltd.
- Midatech Pharma PLC
- Oncogenerix, Inc.
- Pharmida AG
- Point Therapeutics, Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.